Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 2
Submit an article Journal homepage
715
Views
12
CrossRef citations to date
0
Altmetric
Research Article

Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease

Heather LandauMemorial Sloan-Kettering Cancer Center, New York, NY, USACorrespondence[email protected]
,
Neeta Pandit-TaskarMemorial Sloan-Kettering Cancer Center, New York, NY, USA
,
Hani HassounMemorial Sloan-Kettering Cancer Center, New York, NY, USA
,
Adam CohenFox Chase Cancer Center, Philadelphia, Pennsylvania
,
Alex LesokhinMemorial Sloan-Kettering Cancer Center, New York, NY, USA
,
Nikoletta LendvaiMemorial Sloan-Kettering Cancer Center, New York, NY, USA
,
Pamela DrullinskyMemorial Sloan-Kettering Cancer Center, New York, NY, USA
,
Philip SchulmanMemorial Sloan-Kettering Cancer Center, New York, NY, USA
,
Suresh JhanwarMemorial Sloan-Kettering Cancer Center, New York, NY, USA
,
Elizabeth HooverMemorial Sloan-Kettering Cancer Center, New York, NY, USA
,
Christina BelloMemorial Sloan-Kettering Cancer Center, New York, NY, USA
,
Elyn RiedelMemorial Sloan-Kettering Cancer Center, New York, NY, USA
,
Stephen D. NimerMemorial Sloan-Kettering Cancer Center, New York, NY, USA
&
Raymond L. ComenzoTufts Medical Center, Boston, Massachusetts
 show all
Pages 275-281 | Received 10 Mar 2011, Published online: 23 Sep 2011

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Tony Huynh, Elise Corre, Marie-Paule Lemonnier, Rémy Duléry, Zora Marjanovic, Nabaz Jaff, Simona Lapusan, Mohamad Mohty, Laurent Garderet & Paul Coppo. (2021) Role of D(T)PACE-based regimens as treatment of multiple myeloma with extramedullary relapse or refractory disease. Leukemia & Lymphoma 62:9, pages 2235-2241.
Read now

Articles from other publishers (11)

Yating Li, Zhengxu Sun & Xiaoyan Qu. (2022) Advances in the treatment of extramedullary disease in multiple myeloma. Translational Oncology 22, pages 101465.
Crossref
Xiao Hu, Cherng-Horng Wu, Janet M. Cowan, Raymond L. Comenzo & Cindy Varga. (2021) Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy. Annals of Hematology 101:2, pages 369-378.
Crossref
Yujia Zhai, Dai Yuan, Xueling Ge, Shunfeng Hu, Peipei Li, Xiaosheng Fang, Ying Li, Xiangxiang Zhou & Xin Wang. (2021) Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety. Frontiers in Oncology 11.
Crossref
Megan H. Jagosky & Saad Z. Usmani. (2020) Extramedullary Disease in Multiple Myeloma. Current Hematologic Malignancy Reports 15:2, pages 62-71.
Crossref
Dangui Chen, Bing Chen & Fusheng Yao. (2018) Doxorubicin-Loaded PEG-CdTe Quantum Dots as a Smart Drug Delivery System for Extramedullary Multiple Myeloma Treatment. Nanoscale Research Letters 13:1.
Crossref
Shaji K. Kumar, Jacob P. Laubach, Thomas J. Giove, Maureen Quick, Rachel Neuwirth, Godwin Yung, S. Vincent Rajkumar & Paul G. Richardson. (2017) Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. British Journal of Haematology 178:5, pages 756-763.
Crossref
Junling Zhuang, Yi Da, Hui Li, Bing Han, Xia Wan, Tienan Zhu, Miao Chen, Minghui Duan, Ying Xu, Yongqiang Zhao, Ti Shen, Yongji Wu & Daobin Zhou. (2014) Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma. Leukemia Research 38:2, pages 188-193.
Crossref
Xin Jin, Shujing Lu, Xue Xing, Lili Wang, Dongliang Mu, Mingjing He, Haiyun Huang, Xin Zeng & Qianming Chen. (2013) Thalidomide: features and potential significance in oral precancerous conditions and oral cancer. Journal of Oral Pathology & Medicine 42:5, pages 355-362.
Crossref
Alessandra Romano, Concetta Conticello & Francesco Di Raimondo. (2013) Bortezomib for the treatment of previously untreated multiple myeloma. Immunotherapy 5:4, pages 327-352.
Crossref
Ruben Niesvizky, Tomer M. Mark, Maureen Ward, David S. Jayabalan, Roger N. Pearse, Megan Manco, Jessica Stern, Paul J. Christos, Lena Mathews, Tsiporah B. Shore, Faiza Zafar, Karen Pekle, Zhaoying Xiang, Scott Ely, Donna Skerret, Selina Chen-Kiang, Morton Coleman & Maureen E. Lane. (2013) Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization. Clinical Cancer Research 19:6, pages 1534-1546.
Crossref
Utkarsh PainulyShaji Kumar. (2013) Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma. Clinical Medicine Insights: Oncology 7, pages CMO.S7764.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.